Survival benefit of D2 lymphadenectomy in patients with gastric adenocarcinoma

Citation
Lf. Onate-ocana et al., Survival benefit of D2 lymphadenectomy in patients with gastric adenocarcinoma, ANN SURG O, 7(3), 2000, pp. 210-217
Citations number
29
Categorie Soggetti
Oncology
Journal title
ANNALS OF SURGICAL ONCOLOGY
ISSN journal
10689265 → ACNP
Volume
7
Issue
3
Year of publication
2000
Pages
210 - 217
Database
ISI
SICI code
1068-9265(200004)7:3<210:SBODLI>2.0.ZU;2-0
Abstract
Background: A definite resolution to the controversy on the optimal extensi on of lymph node dissection (LND) in gastric cancer has not been achieved. Surgical morbidity and survival of DI and D2 LND are compared by multivaria te analysis. Methods: A retrospective cohort study of 219 patients with gastric cancer a nd curative resection performed according to Japanese rules. D1 dissection was performed in 106 cases and D2 in 113. The logistic regression model was used to define risk factors for surgical morbidity and the Cox model to de termine prognostic factors. Results: Surgical morbidity occurs in 16.9% and 19.5% in D1 and D2 LND, res pectively (P = .7). The morbidity determinants were operation blood loss. s plenectomy, pancreaticosplenectomy, antrum location, low serum albumin. tot al gastrectomy, and metastatic nodal ratio (P < .0001), but not D2 LND. Fiv e-year survival was 35.1% for D1 and 64% for D2 LND (P < .039). The prognos tic factors were T stage, N stage, serum albumin level, total gastrectomy, D2 LND, and comorbidity (P < .0001). Conclusions: The increment of surgical morbidity and mortality rates attrib uted to D2 LND is largely caused by the effect of splenectomy and pancreati cosplenectomy. A significant survival benefit because of D2 LND was found. The results support the value of extended LND in the surgical treatment of gastric cancer.